RUGADA SYNDROME displays characteristic electrocardiographic (ECG) changes consisting of ST elevation in the anterior chest leads (V 1 -V 3 ) and incomplete right bundlebranch block. It often presents with syncope or sudden death.
CASE REPORT
A previously healthy 16-year-old Philippino male student was found by his mother, a nurse, at home in respiratory distress. She felt no pulse, commenced basic life support, and called an ambulance. The paramedic crew administered 1 mg of epinephrine intravenously. An automatic external defibrillator identified a shockable rhythm, ventricular fibrillation (VF), and delivered a single 200 J DC shock to restore sinus rhythm. The patient was promptly transported to the emergency department (ED).
The patient had no previous medical history and was taking no medications. He denied use of recreational drugs. His family had moved to the United Kingdom from the Philippines before he was born. A paternal uncle had died in his sleep at age 26 without a diagnosis.
On arrival in the ED, he was tachycardic and hypertensive; he had a Glasgow coma score of 9, was agitated, showed decorticate posturing, and required intubation and ventilation. A brief neurologic examination revealed no focal neurologic signs; but because of the concern of possible intracranial pathology and seizure activity, 1 g of phenytoin was administered intravenously. A 12-lead electrocardiogram performed in the ED revealed a sinus tachycardia with incomplete right bundle-branch block and anterior ST-segment abnormalities. There was no prolongation of the QT interval (Fig 1) . Routine blood samples were taken, including a toxicology screen; none of which was abnormal. Arterial blood gas analysis revealed a moderate metabolic acidosis, assumed to be secondary to the period of low cardiac output. The patient was transferred to the intensive care unit. A contrast computed tomography scan of his brain was normal. Cardiovascular stability was maintained throughout.
He was extubated the following afternoon and remained hemodynamically stable. The heart was structurally normal on transthoracic echocardiography. He remained in the ICU for a further 36 hours because of an acute confusional state, which resolved without specific treatment, and was then transferred to the cardiologists for further investigation of his arrhythmia.
At this stage, a presumptive diagnosis of Brugada syndrome was made. An ajmaline challenge was negative. Ajmaline, a class IA antiarrhythmic agent available in the United Kingdom, is used as a pharmacologic provocation test to identify individuals with Brugada syndrome. The test involves the administration of 1 mg/kg of ajmaline, to a maximum dose of 50 mg, under continuous ECG monitoring, to identify the changes in J-point elevation characteristic of the syndrome in serial ECGs recorded at 60-second intervals over a 10-minute period. However, the patient was still receiving phenytoin, which may inhibit the typical ST changes seen in Brugada syndrome with pharmacologic provocation. Electrophysiologic studies failed to show any other substrate for VF. The patient's father also had resting ECG changes consistent with Brugada syndrome (ie, partial right bundle-branch block in V1 and ST elevation in V 1 and V 2 ) (Fig 2A) and underwent an ajmaline challenge test (Fig 2B) . The increased J-point and ST elevation on the father's ECG, after ajmaline, confirmed the diagnosis of Brugada syndrome in this family. There are 3 types of ECG abnormalities associated with Brugada syndrome, which are shown in Figure 3 . The degree of ST elevation seen is consistent with a type 2 response. In Figure 4 , the maximal type 1 response to ajmaline, with coved ST elevation in leads V 1 and V 2 , is shown. This can be seen on resting ECGs in some individuals without any pharmacologic challenge and is associated with a higher risk of sudden cardiac death.
In view of the documented VF arrest, it was decided that the patient should have an implantable cardioverter defibrillator (ICD). The ICD insertion was performed a few days later under general anesthesia. Induction with fentanyl, 100 g, propofol, 150 mg, and atracurium, 30 mg, was performed with full, noninvasive monitoring, including 5-lead ECG, blood pressure measurement, oxygen saturation, end-tidal carbon dioxide, and anesthetic gas analysis. External adhesive defibrillation pads were positioned before induction. The patient's trachea was intubated, and anesthesia was maintained with oxygen, nitrous oxide, sevoflurane, and intermittent positive pressure ventilation. The ICD was inserted without complication. A crystalloid infusion was commenced, and the patient received about 1500 mL of fluid in total. The ICD was tested twice, and each time transient anterior ST elevation was noted.
At the end of the procedure, muscle relaxation was reversed with neostigmine, 2.5 mg, and glycopyrrolate, 0.5 mg. After the return of spontaneous ventilation, the patient's trachea was extubated. At this point, his arterial oxygen saturation decreased. There was a brief period of laryngeal spasm, which resolved with a small amount of continuous positive-airway pressure. However, he also developed excessive pink frothy sputum consistent with pulmonary edema. An urgent chest radiograph confirmed the pulmonary edema and confirmed the correct placement of the ICD lead. Transthoracic echocardiography excluded a pericardial collection. The patient was transferred to the high-dependency unit for further monitoring and
